EP2996688A1 - Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancer - Google Patents
Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancerInfo
- Publication number
- EP2996688A1 EP2996688A1 EP14726103.6A EP14726103A EP2996688A1 EP 2996688 A1 EP2996688 A1 EP 2996688A1 EP 14726103 A EP14726103 A EP 14726103A EP 2996688 A1 EP2996688 A1 EP 2996688A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- catechin
- composition
- complex
- monomeric
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 title claims abstract description 312
- 229930013915 (+)-catechin Natural products 0.000 title claims abstract description 256
- 235000007219 (+)-catechin Nutrition 0.000 title claims abstract description 256
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 75
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 201000011510 cancer Diseases 0.000 title claims abstract description 19
- 230000002265 prevention Effects 0.000 title description 9
- 150000003862 amino acid derivatives Chemical class 0.000 claims abstract description 21
- 239000002243 precursor Substances 0.000 claims abstract description 16
- 230000003449 preventive effect Effects 0.000 claims abstract description 8
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 75
- 229950001002 cianidanol Drugs 0.000 claims description 64
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 63
- 235000005487 catechin Nutrition 0.000 claims description 63
- 239000004472 Lysine Substances 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 239000004475 Arginine Substances 0.000 claims description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 15
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 239000008346 aqueous phase Substances 0.000 claims description 7
- 150000001450 anions Chemical class 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000009109 curative therapy Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000008247 solid mixture Substances 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- -1 {+)-catechin compound Chemical class 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000000621 bronchi Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 77
- 235000001014 amino acid Nutrition 0.000 description 58
- 235000018977 lysine Nutrition 0.000 description 45
- 229960003646 lysine Drugs 0.000 description 44
- 241000700159 Rattus Species 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 30
- 239000008280 blood Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 28
- 210000002381 plasma Anatomy 0.000 description 22
- 230000036470 plasma concentration Effects 0.000 description 21
- 241000282412 Homo Species 0.000 description 20
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 20
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 14
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 12
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 12
- 230000009471 action Effects 0.000 description 12
- 229940030275 epigallocatechin gallate Drugs 0.000 description 12
- 239000013256 coordination polymer Substances 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 10
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 10
- 229960001285 quercetin Drugs 0.000 description 10
- 235000005875 quercetin Nutrition 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 229960001340 histamine Drugs 0.000 description 9
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 8
- 241000700157 Rattus norvegicus Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000001156 gastric mucosa Anatomy 0.000 description 8
- 229960002591 hydroxyproline Drugs 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 150000000017 (+)-catechin Chemical class 0.000 description 4
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241001416505 Mastomys Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000005063 solubilization Methods 0.000 description 4
- 230000007928 solubilization Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 3
- 241000234435 Lilium Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 229960005337 lysine hydrochloride Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 102100036576 Coiled-coil domain-containing protein 174 Human genes 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 101000715221 Homo sapiens Coiled-coil domain-containing protein 174 Proteins 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 244000081822 Uncaria gambir Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002669 lysines Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000010266 Aggressive Periodontitis Diseases 0.000 description 1
- 102000009133 Arylsulfatases Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 241000237369 Helix pomatia Species 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000826860 Trapezium Species 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000011902 cervical lymphadenopathy Diseases 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 201000005043 chondromalacia Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 201000009019 intestinal benign neoplasm Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 201000006727 periodontosis Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Definitions
- composition based on (+) - catechin and amino acid complex for the treatment and prevention of cancer
- the present invention relates to an oral gastroenteric composition
- an oral gastroenteric composition comprising a monomeric (+) - catechin compound and at least one basic amino acid for mammals, and in particular to humans.
- Polyphenols are a family of organic molecules widely present in the plant kingdom. They are characterized, as the name indicates, by the presence of several phenolic groups associated in structures generally of high molecular weight. These compounds are the products of the secondary metabolism of plants.
- (+) - catechin in its monomeric form is directly obtained from the extract of Wncaria Gambir.
- Such a composition is already known, for example, from US Pat. No. 4,285,964 in the context of the treatment of chronic degenerative diseases of connective tissues.
- degenerative diseases the most well known and widespread in humans are, for example, osteoarthritis, chondromalacia and periodontosis.
- composition comprising a monomeric (+) - catechin compound and at least one basic amino acid is a drug in which the active substance is monomeric (+) - catechin
- US 4,285,964 is primarily directed to an injectable composition. However, this document extrapolates in the process the injectable composition aforesaid to obtain an oral formulation by drying the injectable composition.
- the present invention relates to a new use of the oral composition mentioned at the beginning for the curative treatment and / or preventive cancer, preferably hepatocellular, said monomeric (+) - catechin having a molar equivalence ratio relative to said at least one basic amino acid or a basic amino acid derivative (or a precursor amino acid) between 1: 1 and 1: 2.5.
- This article describes the treatment of intestinal tumors in mice with pure monomeric (+) - catechin administered orally, and thus certainly not associated with one or more amino acids.
- this article states that because of its high oral bioavailability, monomeric (+) - catechin is a promising active agent for the treatment of a wide variety of epithelial tumors in mammals, preferably in humans. To be human.
- composition based on monomeric (+) - catechin and at least one basic amino acid or at least one derivative of an acid
- the basic amine when administered orally, allows treatment and prevention, preferably improved, of cancer in the mammal, and in particular in humans.
- composition according to the invention which are the following:
- said molar equivalence ratio is between 1: 1 and 1: 2.
- said molar equivalence ratio is a ratio of 1: 1 or 1: 2.
- said molar equivalence ratio is greater than or equal to 1: 1, in particular greater than 1: 1.
- said molar equivalence ratio is less than or equal to 1: 2.5.
- said molar equivalence ratio is less than 2.5, more particularly less than or equal to 1: 2.
- said molar equivalence ratio is less than 2.
- said molar equivalence ratio is greater than or equal to 1: 1, in particular greater than 1: 1.
- said molar equivalence ratio is less than or equal to 1: 2.5.
- said molar equivalence ratio is less than 1: 2.5, more particularly less than or equal to 1: 2.
- said molar equivalence ratio is less than 1: 2.
- the molar equivalence ratio is between 1: 1.5 and 1: 2.5, preferably between 1: 1.5 and 1: 2.
- said molar equivalence ratio is greater than or equal to 1, 00: 1, 00 and less than or equal to 1, 00: 2,50.
- said molar equivalence ratio is greater than or equal to 1.00: 1, 00 and less than or equal to 1.00: 50.
- said molar equivalence ratio is greater than or equal to 1.00: 1, 50 and less than or equal to 1.00: 2.00.
- said molar equivalency ratio is greater than or equal to, 00: 1, 50 and less than or equal to 1.00: 2.50.
- said composition is used in the form of a (+) - catechin complex and at least one basic amino acid or at least one derivative of a basic amino acid, said complex having an equivalence ratio molar amount of said monomeric (+) - catechin with respect to said at least one basic amino acid or said at least one basic amino acid derivative is between 1: 1 and 1: 2.5 (hereinafter referred to as a complex [ C: AA / 1: 1 - 1: 2.5]).
- said molar equivalence ratio is between 1: 1 and 1: 2.
- said molar equivalence ratio is a ratio of 1: 1 or 1: 2.
- said molar equivalence ratio is greater than or equal to 1: in particular greater than 1: 1.
- said molar equivalence ratio is less than or equal to 1: 2.5.
- said molar equivalence ratio is less than 2.5, more particularly less than or equal to 1: 2.
- said molar equivalence ratio is less than 2.
- said molar equivalence ratio is greater than or equal to 1: 1, in particular greater than 1: 1.
- said molar equivalence ratio is less than or equal to 1: 2.5.
- said molar equivalence ratio is less than
- said molar equivalence ratio is less than 1: 2.
- the molar equivalence ratio is between 1: 1, 5 and 1: 2.5, preferably between 1: 5 and 1: 2.
- said molar equivalence ratio is greater than or equal to 1, 00: 1, 00 and less than or equal to 1, 00: 2,50.
- said molar equivalence ratio is greater than or equal to 1.00: 1, 00 and less than or equal to 1.00: 1, 50.
- said molar equivalence ratio is greater than or equal to 1.00: 1, 50 and less than or equal to 1.00: 2.00.
- said molar equivalence ratio is greater than or equal to 1.00: 1, 50 and less than or equal to 1.00: 2.50.
- said at least one basic amino acid is lysine.
- the oral bioavailability in humans of (+) - catechin ingested in the form of monomeric (+) - catechin complex is much greater [1263 + 88 ng h / min (75780 ng / ml) for 0.920 g of monomeric (+) - catechin ingested as 5 g of complex] to that of monomeric (+) - catechin ingested alone [832 + 150 ng h / ml (49920 ng min / ml) for an equivalent amount of 0.920 g of an oral intake of pure monomeric (+) - catechin], ie + 52% increase in bioavailability thanks to the complex.
- the solubility of the lysine salts of (+) - catechin reached at 400g per liter of water while the (+) - catechin itself under the same conditions has a solubility of 0.9g per liter. .
- (+) - catechin administered orally in the form of a [C: AA / 1: 1 - 1: 2.5] complex gives a maximal piasmatic concentration of free (+) - monomeric catechin c (max) more than doubled compared to that obtained with the same dose (+) - pure monomeric catechin ingested under the same conditions: c (max) of 571 ng for 1 g of (+) - catechin ingested in the form of a complex against 280 ng for 1 g of (+) - catechin monomer ingested as is, an increase of + 103%.
- (+) - catechin is generally well tolerated, the only complaints at high doses are stomach heaviness which could then be eliminated or at least reduced by the use of the [C: AA / 1: 1 - 1: 2.5] as part of a long-term treatment.
- (+) - catechin once injected, is rapidly metabolized and eliminated from the body (within one hour after the injection, nearly 90% of the free monomeric (+) - catechin content was removed from the blood).
- a peak of free monomeric (+) - catechin concentration in the blood is observed within one hour after absorption, and a 50% decrease in this content after two hours. hours.
- (+) - catechin chiorhydrolysinate In rats ingesting 150 mg / kg of (+) - catechin chiorhydrolysinate, the free (+) - catechin bioavailability in the blood is 132349 ng min / ml (2206 ng h / ml) whereas in humans the ingestion of 1.5 g of the same (+) - catechin chiorhydrolysinate gives a bioavailability of 75780 ng min / ml (1263 ng h / ml). Considering the fact that the metabolism is accelerated in the rat we find, for bioavailability studies mentioned later, in the situation of results transposable to humans (see Tables 4 and 2).
- monomeric (+) - catechin is an alternative to heavier treatments such as radiation or chemotherapy, in the treatment of cancer, particularly hepatocellular cancer.
- said at least one basic amino acid is lysine.
- said complex is a complex comprising a lysine molecule for a monomeric (+) - catechin molecule.
- said complex is a complex comprising an arginine molecule for a monomeric (+) - catechin molecule.
- said complex is a complex comprising two lysine molecules for a monomeric (+) - catechin molecule.
- (+) - catechin complex with two lysines is by far the best combination in all experiments to improve the bioavailability of monomeric (+) - catechin orally
- said complex is a complex comprising two arginine molecules for a monomeric (+) - catechin molecule.
- said complex is a complex comprising a lysine molecule and an arginine molecule for a monomeric (+) - catechin molecule.
- the composition according to the invention is characterized in that said complex is in salt form of said complex, said salt comprising said complex, said complex comprising at least one proton derived from at least one acid and at least one anion derived from said at least one acid, said salt having said proton in equimolar amount relative to that in basic amino acid or basic amino acid derivative.
- said at least one acid is preferably chosen from ascorbic acid, acetic acid, citric acid and hydrochloric acid.
- said acid is ascorbic acid.
- ascorbic acid is that of a vitamin supplement. Moreover, since this acid is also an antioxidant, it plays a synergistic antioxidant role compared to that of (+) - catechin.
- said composition is characterized in that it further comprises one or more biocompatible excipients.
- the content of (+) - catechin complex with said basic amino acid or said at least one derivative of a basic amino acid is between 15 and 95% by weight relative to the total weight of said composition, preferably between 60 and 90%, advantageously 65 to 85%.
- the composition is in liquid form or in solid form, preferably water-soluble, in particular in the form of powder, tablet, or tablet.
- the composition in liquid form has, in a solution 0.01 molar at 25 ° C, a pH equal to or greater than 3 (that is to say the theoretical pH of a salt [C: Lys: H + : A " ] in a 1: 0.5 molar equivalence ratio), preferably between 4 and 1 1, advantageously between 4.5 and 9.
- the composition according to the invention is a solid composition, with a pH equal to or greater than 3, preferably between 4 and 11, advantageously between 4.5 and 9, when it is dissolved in 0.01.
- M at 25 ° C including monomeric (+) - catechin and said at least one basic amino acid or said at least one basic amino acid derivative, and optionally at least one acid, as precursors of said complex or salt of the complex, as a combined preparation for simultaneous oral use, said complex forming oral post-administration.
- the solid composition according to the invention comprises monomeric (+) - catechin and said at least one basic amino acid or said at least one basic amino acid derivative in a molar equivalence ratio of between 1: 1 and 1: 2 5.
- said molar equivalence ratio is greater than or equal to 1: in particular greater than 1: 1.
- said molar equivalence ratio is less than or equal to 1: 2.5.
- said molar equivalence ratio is less than 1: 2.5, more particularly less than or equal to 1: 2.
- said molar equivalence ratio is less than 1: 2.
- the molar equivalence ratio is between 1: 1.5 and 1: 2.5, preferably between 1: 1.5 and 1: 2.
- said molar equivalence ratio is greater than or equal to 1, 00: 1, 00 and less than or equal to 1, 00: 2,50.
- said molar equivalence ratio is greater than or equal to 1.00: 1, 00 and less than or equal to 1.00: 1, 50.
- said molar equivalency ratio is greater than or equal to, 00: 1, 50 and less than or equal to 1.00: 2.00.
- said molar equivalence ratio is greater than or equal to 1.00: 50 and less than or equal to 1.00: 2.50.
- the monomeric (+) - catechin and said at least one basic amino acid, or said at least one basic amino acid derivative are precursors which participate, in an aqueous medium, in a complexation reaction to form the complex according to the invention.
- the complex is formed in vivo in the gastrointestinal tract in contact with water saliva or water contained in the stomach bowl.
- the composition according to the invention is a solid composition comprising monomeric (+) - catechin and said at least one basic amino acid or said at least one basic amino acid derivative, and optionally at least one acid, as precursors of said complex or salt of the complex, as a combined preparation for simultaneous oral use in solution in an aqueous phase, said complex forming oral pre-administration, said monomeric (+) - catechin and said at least one basic amino acid or said at least one basic amino acid derivative being present in a molar equivalence ratio of from 1: 1 to 1: 2.5.
- said molar equivalence ratio is greater than or equal to 1: 1, in particular greater than 1:
- said molar equivalence ratio is less than or equal to 1: 2.5.
- said molar equivalence ratio is less than 1: 2.5, more particularly less than or equal to 1: 2.
- said molar equivalence ratio is less than 1: 2.
- the molar equivalence ratio is between 1: 1.5 and 1: 2.5, preferably between 1: 1.5 and 1: 2.
- said molar equivalence ratio is greater than or equal to 1, 00: 00 and less than or equal to, 00: 2,50.
- said molar equivalence ratio is greater than or equal to, 00: 1, 00 and less than or equal to 1, 00: 1, 50.
- said molar equivalence ratio is greater than or equal to 1.00: 50 and less than or equal to 1.00: 2.00.
- said molar equivalence ratio is greater than or equal to 1.00: 1, 50 and less than or equal to 1.00: 2.50.
- the complex is formed as soon as the composition is put into aqueous solution, that is to say before oral administration.
- said oral composition is characterized in that it is used for the prevention and treatment of a variety of forms of cancer, including chronic or non-chronic leukemias, liver, prostate, breast, breast cancer uterus, testes, bladder, kidneys, lungs, bronchi, bones, mouth, esophagus, stomach, pancreas, colon-rectal, lymphoma, myeloma but not exclusively.
- forms of cancer including chronic or non-chronic leukemias, liver, prostate, breast, breast cancer uterus, testes, bladder, kidneys, lungs, bronchi, bones, mouth, esophagus, stomach, pancreas, colon-rectal, lymphoma, myeloma but not exclusively.
- said oral or injectable (parenteral) composition prevents tumors from spreading, helps the body to heal after surgical removal of cancers and reduces the toxic effect of others. drugs used in chemotherapy. It is further demonstrated here that said composition also reduces the destruction of connective tissue and in particular that of collagen fibers during radiotherapy.
- compositions based on the complex according to the invention are indicated in the appended claims.
- the present invention also relates to the use of a complex-based oral therapeutic composition or complex salt according to the invention for the treatment and / or prevention of cancer.
- the present invention also relates to the use of the composition according to the invention, for the manufacture of a therapeutic oral composition for the treatment and prevention of cancer in the mammal, and in particular in humans.
- Figure 1 illustrates the NMR spectra of the monomeric (+) - catechin complex and lysine for a 1: 2 molar equivalence ratio (a) and a 1: 1 molar equivalence ratio (b).
- Figure 2 illustrates the NMR spectra of the monomeric (+) - catechin and arginine complex for a 1: 2 molar equivalence ratio (a) and a 1: 1 molar equivalence ratio (b).
- FIG. 3 illustrates the evolution of plasma concentrations (ce) in free (+) - catechin measured in humans in ng / ml over time T (hour) after the assimilation of (+) - catechin hydrochloride (rich in (+) - monomeric catechin at 61% by weight, group A) and a gram of pure monomeric (+) - catechin (group B).
- Figure 4 illustrates the X-ray diffraction pattern (powder) of the monomeric (+) - catechin complex and lysine for a 1: 2 molar equivalence ratio.
- FIG. 5 illustrates the evolution of the free monomeric (+) - catechin concentration in the plasma as a function of the molar equivalence ratio between monomeric (+) - catechin and Lysine: 1:
- Examples 1 to 6 and Comparative Examples 1 to 5 relate to the results of oral bioavailability and anticancer activity obtained in the mammal (rat and human) for the composition based on the [C: AA / 1: 1 - 1: 2.5] according to the invention.
- Comparative Examples 6 to 10 describe the oral bioavailability results obtained in the rat for the composition based on the mixture of monomeric (+) - catechin and at least one basic amino acid or of at least one derivative of a basic amino acid in a molar equivalence ratio of between 1: 1 and 1: 2.5, preferably between 1:
- (+) - catechin contents in the blood correspond to the levels of monomeric free (+) - catechin.
- Bioavailability is the proportion of free (+) - monomeric catechin found in the body relative to the amount initially administered.
- (+) - catechin can be absorbed in the form of the [C: AA] complex or in the form of pure monomeric (+) - catechin, that is to say i.e. not associated with at least one basic amino acid or at least one basic amino acid derivative.
- (+) - catechin having been absorbed, the presence in the blood of free monomeric (+) - catechin, that is to say in a non-conjugated form, conjugated (+) - catechin, i.e., which has been derivatized by the mammalian metabolism.
- the derivatized monomeric (+) - catechin arises from the cycle of elimination of free monomeric ia (+) - catechin in blood by metabolism (for example and without limitation, by the enterohepatic cycle).
- phase I reactions and phase II reactions are distinguished:
- phase I reactions comprise the oxidation reactions which are predominantly localized in the hepatic microsomes; reduction reactions that are much less frequent and less well explored; and the hydrolysis reactions that are a common metabolic pathway that occurs in the liver, in different tissues and even in the plasma; and then
- the derivatives resulting from the phase I reactions are then conjugated. It is this conjugation that constitutes the phase II reactions, including glucuronecrombination, which involves the conjugation of these derivatives with glucuronic acid.
- a specific proportion (or content) of free (+) - monomeric catechin in the blood after oral administration of monomeric (+) - catechin corresponds to a determined bioavailability.
- the rats were orally administered with a volume of 5 ml of a solution of active product.
- the blood was collected in EDTA-coated tubes and centrifuged at 3000 rpm (rotation per minute) at room temperature. for 45 minutes, and then for 15 minutes at a temperature of 4 ° C. the plasma was then collected and stored at -70 ° C before analysis.
- the reference plasmas were collected internally, from rats and cows not treated with the active substance, and then stored at -20 ° C.
- the free (+) - catechin was extracted from the plasma with a solution of phosphoric acid, EDTA and ascorbic acid to be subsequently purified by SPE (for solid phase extraction) in particular, it is a Oasis TM HLB extraction and analyzed by LC-MS / MS. Quantification was performed using a standard calibration procedure with internal standard (IS) of (+/-) - catechin-2,3,4-3 C3.
- the free (+) - catechin content includes not only the monomeric free (+) - catechin content isolated from the plasma, but also its isomeric forms which result from the isomerization of monomeric free (+) - catechin related to the conditions of extraction of the free (+) - catechin from said plasma.
- the procedure is identical with respect to the extraction and quantification of quercetin or free ECGC in the blood.
- the procedure is the same as that applied for free (+) - catechin, except that an additional step purification by SPE is performed.
- This additional step consists in treating the sample with a digestive solution of arylsulfatase and glucoronidase, in order to extract the active substance from the plasma cells.
- the total (and) concentration in (+) - catechin (free or derivatized) is calculated by measuring, for example by the trapezoid method, the area under the evolution curve of the plasma concentrations (ce) measured in ng / ml over time after oral administration of the (+) - monomeric catechin source.
- (+) - catechin was prepared from stock (+) - catechin and then stored at -20 ° C.
- Catechin-C13 (reference: 719579, purity 99.3% by weight) produced by Sigma Aldrich, was used as SI.
- HPLC aqueous mobile phase formic acid (concentrated to 0.1% by volume);
- mobile phase B HPLC acetonitrile solution containing formic acid at a level of 0.1% by volume
- the complex corresponds to a molecular construct in which the monomeric (+) - catechin is bound to said at least one amino acid, or to said at least one basic amino acid derivative, by hydrogen bridge bonds.
- the monomeric (+) - catechene corresponds to a polyphenol present in the form of a monomer.
- the basic amino acid has a radical which is positively charged at neutral pH.
- the basic amino acid derivative is defined in the context of the present invention as a molecule derived from a basic amino acid, and which results from one or more chemical transformations operated on this amino acid.
- the complex in salt form or not
- the amino acid precursor may be a glucuronide or an amino acid glucuronoside, which, once absorbed, is converted by the organism into amino acid, by the action of the amino acid precursor.
- ⁇ -glucuronidase enzymes ⁇ -glucuronidase enzymes.
- Example 1 Preparation of a monomeric (+) - catechin complex and lysine 1a.
- the (+) - catechin extracted comprises at least trace water.
- (+) - catechin may be added to a solution of two equivalents of lysine brought to a temperature between 40 ° C to 45 ° C with stirring.
- the solution is then filtered on a beaker and washed with 50 ml of distilled water and then dried with evaporation of the water first at the rotavapor and then at the vacuum ramp (for 4 hours at a temperature of 50 ° C.).
- the product obtained is not soluble in deuterated methanol but in deuterated water (D 2 0, solvent used for RN analysis).
- the NMR spectrum obtained is illustrated in FIG.
- the spectra are illustrated in FIG. 4.
- the JECatLysH sample is associated with a DRX spectrum which does not appear to be an overlap of the spectra of monomeric (+) - catechin and of the hydrochloride of lysine, thus showing the formation of a complex and not a mixture of the two components.
- the spectra for the three mixtures of monomeric catechin (+) - catechin and non-protonated lysine show no crystallinity index for these compositions, which indicates that for these references JE149b, JE 50, JE151 there is formation of a composition in the amorphous crystalline state, contrary to what is observed for the mixture JECatLysH for which it has been identified a crystal lattice that does not correspond to the superposition of the spectra of lysine hydrochloride and monomeric (+) - catechin.
- the monomeric (+) - catechin complex with lysine in a 1: 1 molar equivalence ratio was synthesized according to the same protocol as that used for the synthesis of the lysine complex.
- Example 1a but decreasing by a factor 2 the amount of lysine such that there is an excess of (+) - catechin which promotes the formation of said complex at a 1: 1 molar equivalence ratio by the lysine deficiency.
- the monomeric (+) - catechin complex with arginine was synthesized according to the same protocol used for the synthesis of the lysine complex of Example 1a.
- the monomeric (+) - catechin complex with arginine was synthesized according to the same protocol used for the synthesis of the lysine complex of Example 1b.
- This complex salt is administered to a group A of 5 healthy volunteers.
- Table 1 Plasma concentration (ce) of free monomeric (+) - catechin (in nq / ml) for group A as a function of time T (hour)
- FIG. 3 illustrates the evolution of the plasma concentrations (ce) measured in ng / ml over time T (hour) after oral administration of (+) - catechin hydrochlorrolysinate (curve A), this curve is extrapolated from the data listed in Table 1.
- the area measured, for example by the well known trapezium method of the literature, under the curve indicates the total concentration (and) of free monomeric (+) - catechin assimilated in the plasma measured over a period of six hours starting from ingestion of (+) - catechin as a complex formed with chlorhydrolysinate.
- This parameter makes it possible to calculate, from the data of Table 1, the bioavailability of (+) - catechin expressed in ng h / ml. And is 1263 + 88 ng h / ml for (+) - catechin hydrochlorrolysinate.
- the maximum concentration c (max) corresponds to the peak of the curve.
- the c (max) reached 525 ng / ml. This maximum concentration is at a time T (max) of 0.5 h for group A having received the monomeric (+) - catechin complex.
- a dose of 1 g of pure monomeric (+) - catechin is administered to a group B of 5 healthy volunteers.
- Table 3 Plasma concentration (ce) of free monomeric (+) - catechin (in nq / mi) for group B as a function of time T (hour)
- Figure 3 illustrates the evolution of plasma concentrations (ce) measured in ng / ml over time T (hour) after oral administration of pure (+) - catechin (curve B). This curve is extrapolated from the data listed in Table 3.
- the area measured under the curve indicates the total concentration (and) of free monomeric (+) - catechin assimilated in the plasma measured over a period of six hours from ingestion of pure (+) - catechin.
- This parameter makes it possible to calculate, from the data of Tables 1 and 3, the bioavailability of ia (+) - catechin expressed in ng h / ml. La and is calcined at 1263 + 88 ng h / ml for 1.5 g of (+) - catechin hydrohydrolysinate containing 0.92 g of pure (+) - catechin.
- the maximum concentrations c (max) correspond to the peaks of the curves.
- the c (max) is calculated at 280 ng / ml, ie 258 ng / ml for 0.92 g of pure (+) - catechin corresponding to the dose of (+) - catechin ingested with complex salt [C: Lys: HCl].
- the c (max) reached 525 ng / ml, which corresponds to a 103% increase over pure (+) - catechin.
- Comparative Example 2 Measurement of the oral bioavailability of pure monomeric (+) - catechin and the (+) - catechin and lysine complex in rats
- a dose of 100 mg (per kg of body weight) of pure monomeric (+) - catechin (CP) or a dose of (+) - catechin lysinate equivalent to 100 mg of (+) - catechin was administered in each individual of a sample of 5 Wistar rats.
- Oral bioavailability assessment parameters are given in Table 5 for different sources of (+) - catechin: CP, or different lysine complexes.
- the Act (expressed in%) corresponds to the measurement of the difference between the and obtained with each complex and the and measured for the pure monomeric (+) - catechin, brought back to the bioavailability value for the CP.
- the Act calculated for the [C: Lys / 1: 1] complex is obtained as follows:
- a dose of 100 mg (per kg of body weight) of pure monomeric (+) - catechin (CP) or a dose of (+) - catechin complex equivalent to 100 mg of (+) - catechin was administered in each individual of a sample of 5 Wistar rats.
- Oral bioavailability assessment parameters are given in Table 6 for different sources of (+) - catechin: CP, or different lysine or arginine complexes.
- Comparative Example 4 Measurement of oral bioavailability of pure monomeric (+) - catechin, f +) - catechin and lysine complex, at a molar equivalence ratio of 1: 1 and 1: 5, in the rat
- a dose of 25 mg (per kg of body weight) of pure monomeric (+) - catechin (CP) or a dose of (+) - catechin lysinate equivalent to 25 mg of (+) - catechin was administered in each individual of a sample of 3 Wistar rats.
- Oral bioavailability assessment parameters are given in Table 7a for different sources of (+) - catechin: CP, or different lysine complexes.
- T (max), c (max) and (+) - total catechin present in the blood are given in Table 7b.
- Total (+) - catechin includes free monomeric (+) - catechin and monomeric ⁇ +) - catechin, which has been conjugated by the rat organism.
- Table 7a Oral bioavailability evaluation parameters calculated from the plasma concentration (ce) concentration of free (+) - monomeric catechin (in ng / ml) for each source of (+) - catechin based time T (minute)
- the complex [C: Lys / 1: 2] allows an increase in both levels of free and total plasma (+) - catechin while the complex [C: Lys / 1: 5] significantly decreases these levels compared to the (+) - pure catechin, that is to say, ingested without lysine.
- Example 4 Measurement of the action of monomeric (+) - catechin chlorhydrolvsinate and monomeric (+) - catechin ascorbolysinate on the total incorporation into collagen of 3H-proline in the skin
- the stabilization of lysosome membranes prevents the release of proteolytic enzymes responsible for the degradation of the conjunctive matrix, including collagen. This degradation is at the root of the spread of metastatic cancer cells, whatever the type of cancer (Cell Communication and Signaling 2010, 8:22).
- the skin is a tissue particularly rich in connective matrix and collagen fibers, which gives it all its elasticity.
- Group C received monomeric (+) - catechin hydrochlorrolysinate while group D received monomeric (+) - catechin ascorbolysinate.
- Table 8 action of monomeric (+) - catechin in its complex forms (00 mg / kg) on the level (in dpm / mg) of total incorporation (IT) and in the collagen (IC) of 3H-hydroxyproline in the rat's skin Group
- the rate of incorporation is measured by the disintegration number of radioactive 3 H-hydroxyproline per minute (dpm) per mg dry mass. The higher the number, the higher the concentration of 3H-hydroxyproline.
- this example confirms the protection of the connective tissue in vivo by the oral absorption of complexes of (+) - monomeric catechin orally and therefore the protection of this frame, in particular against intrusion. of cancer cells.
- Table 9 Action of pure monomeric (+) - catechin (100 mg / kg) on the rate (in dpm / mg) of total incorporation (IT) and in the collagen (IC) of 3H-hydroxyproline in the skin of rat
- the rate of incorporation is measured by the disintegration number of radioactive 3H-hydroxyproline per minute (dpm) per mg dry weight. The higher the number, the higher the concentration of 3H-hydroxyproline.
- the Mastomys have a special system of cells storing histamine in the gastric mucosa, these cells can give rise to carcinoid tumors.
- IgE anti-immunoglobulin E
- IgG anti-immunoglobulin E
- a second injection of 1 mg of ovalbumin in 0.0 ml of saline solution is performed in the gastric mucosa in the corpus of anesthetized animals, which causes ulcerous lesion at the level of the injection.
- the 48 rats are divided into three groups: one of 24 and two of 12 individuals.
- the first group of 24 individuals (G1) received a placebo (NaCl solution concentrated at 0.15 M).
- the second group (G2) of 12 individuals was treated with monomeric (+) - catechin hydrochlorrolysinate administered orally twice daily (2 x 300 mg), two days before injection and three days after injection. .
- the third group (G3) of 12 individuals received, under the same conditions as that of the G2 group, the (+) - monomeric catechin chiorhydro (ysinate) at the rate of 100 mg but intraperitoneally.
- the decrease in the level of histamine accumulated in the gastric mucosa results directly from the action of monomeric (+) - catechin on the cell wall that stores histamine.
- the monomeric (+) - catechin makes it possible to reduce the level of histamine assimilated at the level of the gastric mucosa and thus to reduce the number of ulcers.
- a 67-year-old man with lymphoplasmocytic lymphoma (Waldenstom's macroglobulinemia type) was detected in a post-operative blood test at day 0 .
- the diagnosis is based on the electrophoretic detection of a monoclonal peak of immunoglobulins (Ig). This diagnosis was reconfirmed and the peak assayed in a second analysis using the same electrophoresis detection.
- Immunoglobulins play a vital role in the body's defense against aggression and are normally secreted by B cells.
- immunoglobulins are found at a high concentration in the blood and in the urine. They therefore constitute true tumor markers. Their dosage accounts for the number of diseased cells, the extension of the disease and therefore allows to follow its evolution under treatment.
- the infiltration rate remained low and despite IgM values greater than 2000 mg / 100 ml.
- the patient has also not undergone chemotherapeutic treatment. It is therefore considered that it is stabilized.
- left subclavicular cervical lymphadenopathy was first screened on day 0 . Then, 2 weeks later, a left renal adenocarcinoma was detected for this patient, followed by nephrectomy of the left kidney 3 days after detection of adenocarcinoma in this kidney.
- the process comprises an additional step which consists of feeding an acid, preferably ascorbic acid.
- the process comprises an additional step which consists of a feed of an aqueous phase and a solubilization of said mixture in said aqueous phase to form a complex of (+) - catechin and at least one basic amino acid, said complex being solubilized in said aqueous phase.
- the method further comprises a step of adding a biocompatible excipient to said mixture according to the invention.
- said at least one amino acid is selected from the group consisting of lysine and arginine, of natural or synthetic origin, and a mixture thereof.
- composition administered orally was prepared based on a mixture of chlorhydrolysinate (Lys: HCl) in pulverulent form with monomeric pure (+) - catechin with equivalent ratios. molar ratio of 1: 1, 1: 2, 1: 3 and 1: 5.
- a composition which comprises monomeric (+) - catechin and at least one basic amino acid as a precursor of said complex salt [C: Lys: HCl].
- the solution thus obtained is a solution of (+) - catechin chlorhydrolysinate in the form of a complex: the complex obtained in this solution is a monomeric catechin (+) complex and at least one basic amino acid (or its derivative) in a molar equivalence ratio identical to that of the mixture according to the invention.
- a mixture of monomeric (+) - catechin and an amino acid at a molar equivalence ratio of 1: 1 will, once solubilized in the aqueous phase, give a complex solution of de (+) - monomeric catechin and at least one basic amino acid (or its derivative) in a molar equivalence ratio of 1: 1.
- Comparative Example 6 Measurement of the oral and injectable bioavailability of the (+) - catechin and lysine complex, at a molar equivalence ratio of 1: 1 and 1: 2, in the rat
- Table 12a Plasma concentration (ce) of total monomeric (+) - catechin (in ng / ml) as a function of time T (min)
- Table 12b plasma concentration (ce) of free monomeric (+) - catechin (in ng / ml) as a function of time T (min)
- Table 12c Comparison of total plasma concentrations (and) in ng min / ml of free monomeric (+) ⁇ catechin and total (+) - catechin monomeric after intravenous and oral administration of 25 mg / kg of C: Lvs: HCl / 1: 2: 2 in the rat.
- This intravenous injection shows that there are one or two lysine molecules associated with monomeric (+) - catechin, that this (+) - catechin is rapidly removed from the bloodstream.
- the oral ingestion of the complexed form of monomeric (+) - catechin increases the amounts of (+) - free monomeric catechin in the blood, and on the other hand, prolongs the peak maximum concentration.
- Table 13 parameters of T (max), c (max) and of (+) - free catechin present in the blood calculated from the plasma concentration curves (ce) of free (+) - catechin monomeric (in ng / ml) for each source of (+) - catechin as a function of time T (minute)
- Comparative Example 8 Measurement in rats of the effect of the molar equivalence ratio between (+) - catechin and the basic amino acid on the oral bioavailability of the (+) - catechin hydrochlorrolysinate complex according to US Pat. invention
- Table 14 Parameters of T (max), c (max) and (+) - free catechin present in the blood calculated from the plasma concentration (ce) curves of free (+) - monomeric catechin (in ng / ml) for each source of (+) - catechin as a function of time T (minute)
- the value of and (ng min / ml) for the complex salt C: Lys: HCL / 1: 1, 5: 1, 5 plotted in FIG. 5 is 142k ng min / ml, which is better than 1: 1: 1 (127k, reported value) and better than 1: 2.5: 2.5 (105k ng min / ml, reported value) but less than 1: 2: 2 (165k, calculated value).
- Comparative Example 9 Measurement in the Rat of the Nature of the Therapeutic Composition on Oral Bioavailability That the composition administered per os are based on the complex [C: AA / 1: 1 - 1: 2.5] prepared according to method described in Example 1a (1b) or 2a (2b) (see Examples 1 and 2), or that the orally administered composition is a mixture of the desired molar equivalence ratio of (+) - catechin and lysine hydrochloride (also referred to as chlorydrolysinate), the oral bioavailability results are similar (see Table 15 below).
- Table 15 Parameters of T (max), c (max) and (+) - free catechin present in the blood calculated from the plasma concentration (ce) curves of free ia (+) - catechin monomeric (in ng / ml) for each source of (+) - catechin as a function of time T (minute)
- Table 16 parameters of T (max), c (max) and free polyphenol present in the blood calculated from the plasma concentration (ce) curves of the polyphenol ( " in nq / mO for each polyphenol source as a function of time T (minute)
- ** ac measurement of the difference between the and obtained with the complex and the and measured for the QP, brought back to the value of bioavailability for the QP.
- the orally administered composition was prepared based on a mixture of chlorhydrolysinate (Lys: HCl) in powder form with quercetin or pure monomeric EGCG at molar equivalence ratios of 1: 2 for quercetin, and 1: 1, 1: 2, 1: 3 and 1: 5, for EGCG.
- Each of the mixtures is solubilized in water. This solution is then administered per os (PO) to each individual of a group of 5 Wistar rats, at a dose of 25 mg (per kg of body weight) of quercetin or pure monomeric EGCG or a dose of Quertecin or EGCGC lysinate equivalent to 25 mg of polyphenol.
- the measured levels remain below the reliable limits of detection (that is to say below 250 ng / ml), whether for pure EGCG or for its complexed forms. whatever the proportion of chlorhydrolysinate added to epigallocatechin gallate (in a molar equivalency ratio of 1: 1: 1, 1: 2: 2, 1: 3: 3, or 1: 5: 5).
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE20130350A BE1023772B9 (en) | 2013-05-17 | 2013-05-17 | COMPOSITION BASED ON A (+) - CATECHIN AND AMINO ACID COMPLEX FOR THE TREATMENT AND PREVENTION OF CANCER |
PCT/EP2014/059780 WO2014184197A1 (en) | 2013-05-17 | 2014-05-13 | Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2996688A1 true EP2996688A1 (en) | 2016-03-23 |
Family
ID=48951281
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14726103.6A Withdrawn EP2996688A1 (en) | 2013-05-17 | 2014-05-13 | Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancer |
EP14727731.3A Active EP2996686B1 (en) | 2013-05-17 | 2014-05-13 | Oral composition comprising (+)-catechin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14727731.3A Active EP2996686B1 (en) | 2013-05-17 | 2014-05-13 | Oral composition comprising (+)-catechin |
Country Status (12)
Country | Link |
---|---|
US (2) | US9844595B2 (en) |
EP (2) | EP2996688A1 (en) |
JP (2) | JP2016518422A (en) |
CN (1) | CN105392479A (en) |
AU (1) | AU2014267398B2 (en) |
BE (1) | BE1023772B9 (en) |
BR (1) | BR112015028661A2 (en) |
CA (1) | CA2912128A1 (en) |
ES (1) | ES2730947T3 (en) |
MX (1) | MX2015015667A (en) |
SG (1) | SG11201509433RA (en) |
WO (2) | WO2014184197A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1023772B9 (en) * | 2013-05-17 | 2017-08-02 | Valore | COMPOSITION BASED ON A (+) - CATECHIN AND AMINO ACID COMPLEX FOR THE TREATMENT AND PREVENTION OF CANCER |
BE1022579A9 (en) * | 2014-11-10 | 2016-10-06 | Valore | Antimetastatic composition comprising at least one flavanol-type compound |
US10617705B1 (en) | 2019-01-24 | 2020-04-14 | Alps Pharmaceutical Ind. Co., Ltd. | Isoquercitrin compositions |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5616412A (en) * | 1979-07-18 | 1981-02-17 | Kanebo Ltd | Carcinostatic agent |
US4285964A (en) * | 1979-08-30 | 1981-08-25 | Continental Pharma | Salts of (+)-catechine, their preparation and use, and compositions containing these salts |
CH665634A5 (en) * | 1985-08-30 | 1988-05-31 | Joseph Dr Kovacs | Stable soluble catechin complexes - with a double salt of L-lysine, for liver protection and digestive ulcers |
GB2306321A (en) | 1995-10-24 | 1997-05-07 | Anne Child | The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders |
US6939860B2 (en) | 2002-01-08 | 2005-09-06 | Matthias Rath | Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
CA2471932A1 (en) * | 2002-01-11 | 2003-07-17 | Matthias Rath | A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
WO2007137602A1 (en) * | 2006-05-29 | 2007-12-06 | Patent Engineering Trust Reg. | Method of producing a liquid oral or otherwise applicable composition for administration to human beings and animals, liquid oral or otherwise applicable composition and its use of the composition for the manufacture of a product for functional nutrition |
CN1943572A (en) * | 2006-08-21 | 2007-04-11 | 浙江大学 | Oral natural plant formula with anti-sunlight function |
US9211298B2 (en) * | 2012-11-16 | 2015-12-15 | Song Gao | Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses |
BE1023772B9 (en) * | 2013-05-17 | 2017-08-02 | Valore | COMPOSITION BASED ON A (+) - CATECHIN AND AMINO ACID COMPLEX FOR THE TREATMENT AND PREVENTION OF CANCER |
-
2013
- 2013-05-17 BE BE20130350A patent/BE1023772B9/en active IP Right Grant
-
2014
- 2014-05-13 ES ES14727731T patent/ES2730947T3/en active Active
- 2014-05-13 CA CA2912128A patent/CA2912128A1/en not_active Abandoned
- 2014-05-13 BR BR112015028661A patent/BR112015028661A2/en not_active IP Right Cessation
- 2014-05-13 WO PCT/EP2014/059780 patent/WO2014184197A1/en active Application Filing
- 2014-05-13 SG SG11201509433RA patent/SG11201509433RA/en unknown
- 2014-05-13 US US14/889,470 patent/US9844595B2/en not_active Expired - Fee Related
- 2014-05-13 JP JP2016513334A patent/JP2016518422A/en active Pending
- 2014-05-13 JP JP2016513335A patent/JP2016518423A/en active Pending
- 2014-05-13 EP EP14726103.6A patent/EP2996688A1/en not_active Withdrawn
- 2014-05-13 WO PCT/EP2014/059781 patent/WO2014184198A1/en active Application Filing
- 2014-05-13 MX MX2015015667A patent/MX2015015667A/en unknown
- 2014-05-13 AU AU2014267398A patent/AU2014267398B2/en not_active Expired - Fee Related
- 2014-05-13 CN CN201480039349.4A patent/CN105392479A/en active Pending
- 2014-05-13 EP EP14727731.3A patent/EP2996686B1/en active Active
- 2014-05-13 US US14/889,512 patent/US20160095923A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO2014184197A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2014267398A1 (en) | 2015-11-19 |
CN105392479A (en) | 2016-03-09 |
BR112015028661A2 (en) | 2017-07-25 |
JP2016518422A (en) | 2016-06-23 |
AU2014267398B2 (en) | 2019-02-21 |
US20160089358A1 (en) | 2016-03-31 |
EP2996686B1 (en) | 2019-04-03 |
JP2016518423A (en) | 2016-06-23 |
EP2996686A1 (en) | 2016-03-23 |
CA2912128A1 (en) | 2014-11-20 |
WO2014184197A1 (en) | 2014-11-20 |
MX2015015667A (en) | 2016-07-20 |
WO2014184198A1 (en) | 2014-11-20 |
US9844595B2 (en) | 2017-12-19 |
BE1023772B1 (en) | 2017-07-17 |
US20160095923A1 (en) | 2016-04-07 |
BE1023772B9 (en) | 2017-08-02 |
ES2730947T3 (en) | 2019-11-13 |
SG11201509433RA (en) | 2015-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016204061B2 (en) | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients | |
US20010022979A1 (en) | Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions | |
FR2759293A1 (en) | MICROGRANULES CONTAINING CISPLATIN, METHOD OF MANUFACTURE, PHARMACEUTICAL PREPARATION AND USE IN POLYCHIMIOTHERAPY OR IN ASSOCIATION WITH RADIOTHERAPY | |
EP2996686B1 (en) | Oral composition comprising (+)-catechin | |
EP0316408A1 (en) | Method of tumor inhibition in warm-blooded animals | |
EP0280593B1 (en) | Composition on the basis of an amino-acid and vitamins for use in cancer therapy | |
WO1991004737A1 (en) | Osteogenesis promoter | |
NL192682C (en) | Method for preparing a hemin complex, and drug. | |
CN1745746A (en) | Hydroxypropyl-beta-cyclodextrin coating material of borneol an dits preparing method | |
CA2535208A1 (en) | Oral compositions and route of administration for the delivery of a thylakoid extract | |
KR102397659B1 (en) | Anti-inflammatory composition comprising gold nanoparticles containing Hibiscus syriacus callus extract | |
BE897980A (en) | PROCESS FOR THE PREPARATION OF A SOLUTION FOR PHARMACEUTICAL USE CONTAINING A NEW MIXED POLYNUCLEAR IRON (III) COMPLEX AS ACTIVE INGREDIENT | |
EP0542979A1 (en) | Therapeutic composition for sustained release of magnesium | |
CN1118473C (en) | Aqueous soluble steroid compound alkaloid salt, preparation process and medicinal composition containing same | |
CN1167421C (en) | Medicine composition containing pyrroloquinolinequinone for treating saturnism | |
FR3125294A1 (en) | PECTIN POLYSACCHARIDE SELENITE AND METHOD FOR THE PREPARATION AND USE THEREOF | |
EP3237015A1 (en) | Hydrosoluble hydroxybisphosphonic derivatives of doxorubicin | |
JP2017524670A (en) | How to treat iron deficiency | |
EP0412877A1 (en) | Oral galenic form to improve bioavailability | |
CN117045605A (en) | High-stability chlortetracycline hydrochloride soluble powder and preparation method thereof | |
JP2022551528A (en) | Oral pharmaceutical compositions containing cannabinoids and methods for their preparation | |
KR20160018562A (en) | Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancer | |
CN1990047A (en) | Elemene inclusion complex, preparation and preparation process thereof | |
WO2008107569A2 (en) | Cysteine inclusion complexes and compositions containing same | |
FR2632523A1 (en) | Use of an extract obtained from a plant of the Residaceae family, such as mignonette, for the manufacture of a medicament having antalgic or analgesic activity, and process for manufacturing such a medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151215 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: NIEBES, PAUL Inventor name: SCHOENTJES, BRUNO Inventor name: ESTAGER, JULIEN Inventor name: MAY, BRONISLAV, HENRIC Inventor name: RACHIDI, SAID |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20170621 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/194 20060101ALI20190215BHEP Ipc: A61K 31/353 20060101ALI20190215BHEP Ipc: A61K 9/00 20060101ALI20190215BHEP Ipc: A61P 35/00 20060101ALI20190215BHEP Ipc: A61K 9/08 20060101ALI20190215BHEP Ipc: A61K 31/19 20060101ALI20190215BHEP Ipc: A61K 31/198 20060101ALI20190215BHEP Ipc: A61P 35/02 20060101ALI20190215BHEP Ipc: A61K 31/375 20060101AFI20190215BHEP |
|
INTG | Intention to grant announced |
Effective date: 20190307 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VALORE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190718 |